Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis
Clinical Genetics · 2025
DOI: 10.1111/cge.14780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2025. Verfasst von Lucas D Richter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Pancreatitis, Cystic Fibrosis, Genetic Predisposition to Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), National Human Genome Research Institute.
Abstract (Originalsprache)
This study assessed the effect of CFTR pathogenic variant status, detected during prenatal carrier screening, for the incidence and clinical recognition of cystic fibrosis‐related phenotypes. Data were queried from the Vanderbilt University Medical Center clinical genetic database (CGdb), which includes clinically reported pathogenic variants and electronic health records (EHRs) from 2001 to 2023. Based on carrier screening results, we identified individuals heterozygous for a pathogenic CFTR variant and those who tested negative. Logistic regression tested associations between CFTR carrier status and 11 cystic fibrosis (CF)‐related phenotypes. A phenome‐wide association study (PheWAS) was performed to identify additional phenotypic associations, and manual chart review was conducted to evaluate recognition and clinical application of CFTR carrier status in patients diagnosed with pancreatitis. Among 12,082 women tested, CFTR carriers ( n = 451) were at significantly higher risk of developing acute pancreatitis ( p = 3.93 × 10 −6 ; OR = 4.68 [2.43–9.00]). No other CF‐related phenotypes were significantly associated in this female cohort. Manual chart review revealed that CFTR carrier screening results were not clinically correlated with pancreatitis diagnoses. In this large cohort of women tested for prenatal carrier screening, CFTR pathogenic variants relevant to pancreatitis were overlooked, despite informing etiology, management, and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Psychiatry & Behavioral Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Division of General Internal Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Lucas D Richter
Förderung
- NHGRI NIH HHS
- National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH)
- National Human Genome Research Institute
Zitieren
APA
Richter, L. D., Ruderfer, D. M., Peterson, J. F., & Bastarache, L. A. (2025). Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis. Clinical Genetics. https://doi.org/10.1111/cge.14780
Vancouver
Richter LD, Ruderfer DM, Peterson JF, Bastarache LA. Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis. Clinical Genetics. 2025. doi:10.1111/cge.14780
BibTeX
@article{Richter2025,
author = {Richter, Lucas D and Ruderfer, Douglas M and Peterson, Josh F and Bastarache, Lisa A},
title = {Beyond Carrier Status: CFTR Heterozygosity as an Overlooked Clinical Risk Factor for Pancreatitis},
journal = {Clinical Genetics},
year = {2025},
doi = {10.1111/cge.14780}
}
EUVIMED